5
Clinical Trials associated with Anakinra biosimilar(Hamad Medical Corp.)Efficacy of Anakinra in the Management of Patients With COVID-19 Infection in Qatar: A Randomized Clinical Trial
Coronavirus Disease 2019 (COVID-19) was first isolated in Wuhan, China in December 2019. It is rapidly spreading worldwide, posing a severe threat to global health. Many therapeutics have been investigated for the treatment of this disease with inconclusive outcomes.
Anakinra - an interleukin (IL)-1 receptor antagonist - had showed survival benefits in patients with macrophage activation syndrome (MAS) and sepsis and was investigated for the use in COVID-19 infection with promising outcomes.
/ Not yet recruitingPhase 3IIT An open prospective randomized therapeutic trial using ANAKINRA or TOCILIZUMAB alone or in combination with RUXOLITINIB in severe stage 2b and 3 COVID-19 disease - INFLAMMACOV
/ Not yet recruitingPhase 2IIT Anakinra: Efficacy of interleukin-1 pathway inhibitor anakinra for the management of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic stem cell transplantation after high-dose melphalan – A randomized controlled trial - AFFECT-2
100 Clinical Results associated with Anakinra biosimilar(Hamad Medical Corp.)
100 Translational Medicine associated with Anakinra biosimilar(Hamad Medical Corp.)
100 Patents (Medical) associated with Anakinra biosimilar(Hamad Medical Corp.)
100 Deals associated with Anakinra biosimilar(Hamad Medical Corp.)